Quick Answer
Royalty Pharma plc reported Total Revenue of $2.38 billion for fiscal year 2025.
Royalty Pharma plc Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $2.38B | +5.1% |
| 2024 | $2.26B | -3.9% |
| 2023 | $2.35B | +5.2% |
| 2022 | $2.24B | -2.3% |
| 2021 | $2.29B | +7.9% |
| 2020 | $2.12B | +17.0% |
| 2019 | $1.81B | +1.1% |
| 2018 | $1.79B | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $609.29M | +7.9% | +5.3% |
| June 30, 2025 | $578.66M | +7.7% | +1.8% |
| March 31, 2025 | $568.25M | +0.0% | +0.6% |
| September 30, 2024 | $564.69M | +5.3% | +5.1% |
| June 30, 2024 | $537.27M | -0.2% | -5.4% |
| March 31, 2024 | $567.98M | -17.0% | +5.9% |
| September 30, 2023 | $536.31M | -6.5% | -0.4% |
| June 30, 2023 | $538.20M | +0.4% | -21.3% |
- Royalty Pharma plc showed an increase of +5.1% in Total Revenue compared to the prior fiscal year.
- Over the 2018–2025 period, Royalty Pharma plc’s total revenue has grown by 32.5% (from $1.79 billion to $2.38 billion).
- The most recent figure is from Royalty Pharma plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: